Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer

Mingxin Wen; Yongwon Kwon; Yongsheng Wang; Jian-Hua Mao; Guangwei Wei

doi:10.18632/oncotarget.4712

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer

Mingxin Wen, Yongwon Kwon, Yongsheng Wang, Jian-Hua Mao and Guangwei Wei _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:25226-25239. https://doi.org/10.18632/oncotarget.4712

Metrics: PDF 2389 views | HTML 2529 views | ?

Abstract

Mingxin Wen1, Yongwon Kwon2, Yongsheng Wang1, Jian-Hua Mao2, Guangwei Wei1

1Department of Human Anatomy and Key Laboratory of Experimental Teratology, Ministry of Education, Shandong University School of Medicine, Jinan, Shandong, 250012 P.R. China

2Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94127, USA

Correspondence to:

Guangwei Wei, e-mail: [email protected]

Jian-Hua Mao, e-mail: [email protected]

Keywords: UBE2T, prostate cancer, metastasis, vimentin

Received: May 07, 2015 Accepted: July 17, 2015 Published: July 30, 2015

ABSTRACT

Increased expression of ubiquitin-conjugating enzyme E2T (UBE2T) is reported in human prostate cancer. However, whether UBE2T plays any functional role in prostate cancer development remains unknown. We here report the first functional characterization of UBE2T in prostate carcinogenesis. Prostate cancer tissue array analysis confirmed upregulation of UBE2T in prostate cancer, especially these with distant metastasis. Moreover, higher level of UBE2T expression is associated with poorer prognosis of prostate cancer patients. Ectopic expression of UBE2T significantly promotes prostate cancer cell proliferation, motility and invasion, while UBE2T depletion by shRNA significantly inhibits these abilities of prostate cancer cells. Xenograft mouse model studies showed that overexpression of UBE2T promotes whereas UBE2T depletion inhibits tumor formation and metastasis significantly. Collectively, we identify critical roles of UBE2T in prostate cancer development and progression. These findings may serve as a framework for future investigations designed to more comprehensive determination of UBE2T as a potential therapeutic target.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4712

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer

Abstract